-
Sector Analysis
NewAntibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADC-2122 in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADC-2122 in Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADC-2122 in Lung Cancer Drug Details: ADC-2122 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADC-2122 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADC-2122 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADC-2122 in Colorectal Cancer Drug Details: ADC-2122 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ADC-2122 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADC-2122 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADC-2122 in Gastric Cancer Drug Details: ADC-2122 is under development for the...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
NewNet Present Value Model: ADC Therapeutics SA’s ADCT-602
Empower your strategies with our Net Present Value Model: ADC Therapeutics SA's ADCT-602 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
ADC, Inc Pit 008 Mine
The ADC, Inc Pit 008 Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our ADC, Inc Pit 008 Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Bladder Cancer Drug Details: DS-1062 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Transitional Cell Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Metastatic Biliary Tract Cancer Drug...